Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma.
4'Deoxydoxorubicin was evaluated in patients with advanced renal carcinoma. Only one partial remission was noted, and no significant cardiac toxicity was seen on serial evaluation of ejection fractions. Appropriate dose escalations were performed.